ADVENTRX Reports Q4 and Full Year 2010 Financial Results (ANX)

ADVENTRX Pharmaceuticals, Inc. ANX today reported financial results for the fourth quarter and year ended December 31, 2010.

Recent Highlights
- Definitive agreement to acquire SynthRx and purified poloxamer 188
- $47.2 million in cash at March 1, 2011
- Exelbine NDA submitted to and accepted by FDA
- September 1, 2011 PDUFA goal date
- Pipeline expansion activities on-going